Probiotics as vehicles for vaccine administration

益生菌作为疫苗接种的载体

• 批准号: 8938184
• 负责人: Howard Young
• 金额: $ 8.59万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8938184
• 关键词: Antibody Formation; Antigen Targeting; Antigens; Bacteria; Bacterial Proteins; Binding; Chimeric Proteins; GAG Gene; Goals; Immune response; Immunization; KRAS2 gene; Lactobacillus; Measures; Modeling; Mus; Probiotics; Proteins; Recombinants; SIV; Stomach; Surface; Testing; Tumor Antigens; Vaccines; base; microorganism; novel; response; tumor; vector

We have tested this experimental approach by using the SIV GAG protein as a model antigen. Recombinant GAG protein was prepared in the designated vector and the fusion protein obtained was mixed with Lactobacillus acidolphilus. Binding of the GAG protein to the bacteria was observed and mice were administered the microorganisms +/- the SIV GAG protein via stomach gavage over a 3 week period. A strong antibody response was observed in 2 of 4 treated mice after 2 or 3 weeks of immunization. Based on this positive response, we are developing recombinant tumor antigen fusion proteins, i.e. TARP and K-ras, in order to evaluate the host response to these antigens when presented on the surface of Lactobacillus. Upon creation of the appropriate recombinant we will determine if the mice can be protected from KRAS driven tumors.

我们使用 SIV GAG 蛋白作为模型抗原测试了这种实验方法。在指定载体中制备重组GAG蛋白，并将获得的融合蛋白与嗜酸乳杆菌混合。观察到 GAG 蛋白与细菌的结合，并在 3 周内通过胃管饲法向小鼠施用微生物+/- SIV GAG 蛋白。免疫 2 或 3 周后，4 只接受治疗的小鼠中有 2 只观察到强烈的抗体反应。基于这种积极的反应，我们正在开发重组肿瘤抗原融合蛋白，即 TARP 和 K-ras，以评估宿主对这些抗原呈现在乳杆菌表面时的反应。在创建适当的重组体后，我们将确定是否可以保护小鼠免受 KRAS 驱动的肿瘤的侵害。